Teriparatide 20micrograms/80microlitres dose solution for injection 2.4ml cartridge with device
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Teriparatide
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Teriparatide
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Teriparatide on the MHRA register
Movymia 20micrograms/80microlitres dose solution for injection 2.4ml cartridge with pen
Terrosa 20micrograms/80microlitres dose solution for injection 2.4ml cartridge with pen
WHO defined daily dose (DDD)
20 microgram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(7)
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)
Abaloparatide for treating osteoporosis after menopause (TA991)
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Romosozumab for treating severe osteoporosis (TA791)
Osteoporosis (QS149)
Hip fracture: management (CG124)
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 40 · Randomised trials: 9 · 2012–2026
Showing the 50 most relevant studies, sorted by most relevant.
D. Kendler, F. Marin, C. Zerbini, et al.
Lancet, 2017
B. Langdahl, C. Libanati, D. Crittenden, et al.
Lancet, 2017
S. Davis, E. Simpson, J. Hamilton, et al.
Health technology assessment, 2020
A. Díez-Pérez, F. Marin, E. Eriksen, et al.
Osteologie, 2019
Fei Yuan, Wen-Ke Peng, Caihong Yang, et al.
International journal of surgery, 2019
Emma Simpson, Marrissa Martyn-St James, J. Hamilton, et al.
Bone, 2020
Rafael A. Buerba, Akshay Sharma, Chason Ziino, et al.
SPINE, 2018
C. Puvvada, Faiza H Soomro, Hafsa A Osman, et al.
Cureus, 2023
Chuanjian Yuan, Yanchen Liang, Kai Zhu, et al.
Journal of Orthopaedic Surgery and Research, 2023
Tao Pan, Chien-Chun Chang, Hsien-Te Chen, et al.
World neurosurgery, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Parathyroid hormone (PTH) is an endogenous hormone that regulates calcium and phosphate metabolism in bone and kidney.
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
95%
Half-life
[L42590]
Protein binding
Volume of distribution
0.12 L/kg
Metabolism
[L42590]…
Elimination
[L42590]
Clearance
62 L/h
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
- for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide reduces the risk of vertebral and nonvertebral fractures.
[L42590][L42595][L46178][L46183]
- to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
[L42590][L42595][L46178][L46183]
- for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
[L42590][L42595][L46178][L46183]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 196 interactions
[L42605]
Few post-marketing reports illustrate cases of medication errors where patients accidentally received up to a single 800 mcg dose of teriparatide, which is 40 times the recommended dose. Patients experienced nausea, weakness or lethargy, and hypotension. No deaths have been reported from teriparatide overdose.
Additional signs, symptoms, and complications of overdosage may include a delayed hypercalcemic effect, vomiting, dizziness, and headache.
[L42590]
There is no specific antidote for a teriparatide overdosage. Treatment of suspected overdosage should include discontinuation of teriparatide, monitoring of serum calcium and phosphorus, and implementation of appropriate supportive measures, such as hydration.
[L42590]
Similarly, teriparatide's skeletal effects depend upon the systemic exposure pattern. Once-daily administration of teriparatide stimulates new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity.[L42590] Teriparatide mediates its osteoanabolic actions by binding to the N-terminal moiety to PTH type 1 receptors (PTH type 1R), which are G-protein coupled receptors expressed on various cells, including osteoblasts, osteocytes, and renal tubular cells.[A251395] Binding of teriparatide to PTH receptors on osteoblasts activates the downstream PKA- and PKC-dependent signaling pathways that promotes anabolic effects on bone.[A6748][A251395] For example, teriparatide increases expression of pro-osteoclastogenic cytokines like receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor. It also upregulates transcriptional expression of pro-osteoblastogenic growth factors like insulin-like growth factor 1 (IGF1) and fibroblast growth factor 2 (FGF2). Teriparatide also downregulates the synthesis of sclerostin, which is a negative regulator of bone formation. It also promotes the differentiation of osteoblasts.[A251395]
Like endogenous PTH, teriparatide affects calcium and phosphate homeostasis. It causes a transient increase in serum calcium levels and increases urinary calcium excretion. In clinical trials, it also produced transient phosphaturia and mild transient reductions in serum phosphorus concentration.[L42590]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L42590]
[L42590]
[L42590]
[L42590]
[L42590]
[L42590]
Proteins and enzymes this drug interacts with in the body
PMID:11604398 PMID:35932760
Acts by binding to its receptor, PTH1R, activating G protein-coupled receptor signaling .
PMID:18375760 PMID:35932760
Stimulates [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblastic cells PMID:21076856
PMID:10913300 PMID:18375760 PMID:19674967 PMID:27160269 PMID:30975883 PMID:35932760 PMID:8397094
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) .
PMID:30975883 PMID:35932760
PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity .
PMID:20172855 PMID:30975883 PMID:35932760
PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH PMID:35932760
ATC H05AA02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Teriparatide
Additional database identifiers
Drugs Product Database (DPD)
13330
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9606
GenAtlas
PTH
GeneCards
PTH
GenBank Gene Database
V00597
UniProt Accession
PTHY_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9608
GenAtlas
PTHR1
GeneCards
PTH1R
GenBank Gene Database
BC112247
Guide to Pharmacology
331
UniProt Accession
PTH1R_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q411781), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.